Neutrophil-lymphocyte ratio as a prognostic biomarker in high-risk locally advanced kidney cancer

An analysis of the data collected during the S-TRAC study, in which patients with high-risk, localised renal cell carcinoma (RCC) were treated with adjuvant sunitinib (after surgery), showed that sunitinib improved disease-free survival over placebo, but not overall survival. Researchers decided to look at biomarkers for disease-free survival in this study. In this study, a […]

read more

Neutrophil-lymphocyte ratio for predicting survival in sarcomatoid kidney cancer

A recent study of 230 patients with sarcomatoid renal cell carcinoma (RCC) investigated pre-surgery neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio as biomarkers for the prediction of survival. Neutrophil-lymphocyte ratio was assessed 1 to 8 weeks after surgery, and percentage change from pre- to post-surgery was calculated. Pre-surgery neutrophil-lymphocyte ratio was a significant predictor of […]

read more

Neutrophil-lymphocyte ratio may predict survival following surgery for kidney cancer

A recent study published in European Urology Focus┬áreports that the neutrophil-lymphocyte ratio (NLR) in the blood before surgery may be used as a biomarker to predict survival following cytoreductive nephrectomy plus removal of the tumour blood clot (thrombectomy) for renal cell carcinoma (RCC). The study involved 332 patients with metastatic RCC and tumour thrombus. Those […]

read more
Showing all 3 results
  TOP